Invion Ltd. · ASX:IVX
Invion — Shareholder Meeting (November 2024)
20 slides from Invion's shareholder meeting presentation, Nov 14, 2024
Slide 1: Annual General Meeting November 2024
For personal use only ANNUAL GENERAL MEETING November 2024 Next Generation Photodynamic Therapy (PDT) for Cancers and Infectious Diseases ASX: IVX
Slide 2: Disclaimer
DISCLAIMER For personal use only The information in this presentation does not constitute personal investment advice. The presentation is not intended to be comprehensive or provide all information required by investors to make an informed decision on any investment in Invion Limited (Company). In p
Slide 3: Year of Achievements
YEAR OF ACHIEVEMENTS PROGRESSING TOWARDS KEY CLINICAL MILESTONES Patient Recruitment for Ph I/II Non-Melanoma Skin Cancer For personal use only Trial Successful Ph 2 Prostate Cancer Clinical Trial Results Collaboration Hanlim Pharm: Glioblastoma (Preclinical) Combination INV043 + ICI Immunotherapy i
Slide 4: Target Diseases and Indications
TARGET DISEASES AND INDICATIONS PDT FOR TREATMENT OF CANCERS AND INFECTIOUS DISEASES* PRIMARY FOCUS: CANCER (INV043) INFECTIOUS DISEASES For personal use only Multiple cancer indications Broad spectrum antimicrobial activity Ablation and activation of immune response against viruses, bacteria
Slide 5: Results and Findings: Cancer
For personal use only RESULTS AND FINDINGS: CANCER Clinical & Preclinical Data
Slide 6: Phase II Prostate Cancer Clinical Trial
PHASE II PROSTATE CANCER CLINICAL TRIAL INVESTIGATOR-LED PROSTATE CANCER STUDY USING INV043* For personal use only Screening: Men between 50-80 years with 1st cohort of COVID-19 Lockdowns: 10 patients Biopsy proven primary prostate cancer, or dropped out. Remaining treated 25 patients but with inc
Slide 7: Phase II Prostate Trial Results: Sublingual (Systemic)
PHASE II PROSTATE TRIAL RESULTS: SUBLINGUAL (SYSTEMIC) COMPELLING SAFETY, SOLID EFFICACY SIGNALS SAFE AND WELL TOLERATED EFFICACY: 40-44% RESPONSE RATE For personal use only When administered sublingually to patients over 6 cycles of PSMA-PET1 Results PDT treatments (from 2nd cohort, n=16) over 3 mo
Slide 8: Ongoing Phase I/II Trial: Non-Melanoma Skin Cancer
ONGOING PHASE I/II TRIAL: NON-MELANOMA SKIN CANCER THERAGNOSTIC ENDPOINTS • Adaptive: Open label adaptive trial design (3+3 light dose / dose light interval escalation1) enables For personal use only flexibility in size and timing, with option for repeat treatment depending on response • Safety, Dos
Slide 9: Why Skin Cancer?
WHY SKIN CANCER? ATTRACTIVE CLINICAL TRIAL INDICATION For personal use only Relatively Cost Effective Costs to undertake skin cancer trials typically lower than for other routes of administration (eg, intravenous) Faster Path to Market Trials with topical treatments often quicker to complete due to
Slide 10: Evaluation of NMSC Therapies
EVALUATION OF NMSC THERAPIES1 POTENTIAL TO DISPLACE STANDARD OF CARE Non-Melanoma Skin Cancer (NMSC) Phase I/II Clinical Trial (Adaptive Trial Structure): Addressing the unmet need for one of the world’s most common cancers2 For personal use only GOOD INV043 (Topical) Metvix#/ALA PDT Treatment #by G
Slide 11: Treatment Options: Flexibility for Clinicians
TREATMENT OPTIONS: FLEXIBILITY FOR CLINICIANS MULTIPLE PATHWAYS FOR DRUG AND TARGETED LIGHT DELIVERY INV043 can be administered to multiple target indications via different drug and light delivery options For personal use only ROUTES OF DRUG ADMINISTRATION LIGHT ADMINISTRATION OPTIONS MULTIPLE POTEN
Slide 12: Theragnostic Potential
THERAGNOSTIC POTENTIAL MULTIPLE CANCERS, PRECISION CANCER TARGETING, PROTECTIVE IMMUNITY SELECTIVE TARGETING PROTECTIVE IMMUNITY For personal use only Control Treated https://inviongroup.com/videos-reports/ • INV043 selectively retained in malignant but not healthy • Triple Negative Breast Cancer (T
Slide 13: Combination with Immune Checkpoint Inhibitors (ICI)
COMBINATION WITH IMMUNE CHECKPOINT INHIBITORS (ICI) IMPROVING IMMUNOTHERAPY OUTCOMES, PARTNERSHIP POTENTIAL • Immune checkpoint inhibitors (ICI), a type of immunotherapy, is standard of care in treatment of several cancers • Despite widespread use of ICIs, the patient response rate can be as low as
Slide 14: Creating Impact for Treating Cancers Globally
CREATING IMPACT FOR TREATING CANCERS GLOBALLY NEED FOR MORE AFFORDABLE NEW TREATMENTS Commercial Rationale for Photosoft For personal use only Cost of new FDA drugs in 2023 jumped 35% YoY at median price of US$300K1, Works across multiple cancers without need making affordability even to personalise
Slide 15: Target Indications and Timeframes
TARGET INDICATIONS AND TIMEFRAMES MULTIPLE CLINICAL TRIALS AND INDICATIONS DISEASE AREA (CALENDAR YEAR) 1H2024 2H2024 1H2025 2H2025 >CY26 For personal use only CANCER1 Prostate Cancer (Funded by RMWC) Completed Follow up and monitoring Non-Melanoma Skin Cancers (Topical)2 Adaptive study design Anoge
Slide 16: Infectious Diseases
For personal use only INFECTIOUS DISEASES Additional Commercialisation Opportunities
Slide 17: Broad-Spectrum Anti-Microbial Potential
BROAD-SPECTRUM ANTI-MICROBIAL POTENTIAL ANTI-MICROBIAL TREATMENTS – WITHOUT RESISTANCE “Antimicrobial resistance (AMR) is one of the top 10 threats facing humanity” For personal use only World Health Organisation1 Leading Institutions: Viroclinics conducted virus SARS-CoV-2: Omicron tests & ACARE (U
Slide 18: Target Antimicrobial Indications
TARGET ANTIMICROBIAL INDICATIONS COST EFFECTIVE AND ACCELERATED PATHS TO CLINICAL TRIALS HPV PROGRAM FUNDED BY DR.INB PERIODONTAL DISEASE For personal use only HPV distribution profile in women 1 57.7% 44.4% 42.2% 21.4% 3.7% Eastern Asia Central & Sub-Saharan Eastern Western Southern Africa Europe E
Slide 19: Experienced Team
EXPERIENCED TEAM THE RIGHT EXPERTISE FOR SUCCESS PROF THIAN CHEW SCOTT CARPENTER EXECUTIVE CHAIRMAN & CEO PROGRAM DIRECTOR For personal use only • Co-Founder, Chronic Airway Therapeutics • Director Business Development, Starpharma • Advisory Board, Stanford Medicine CARE • Program Manager, AusBiotec
Slide 20: For personal use only
For personal use only Sign up at Invion’s Investor Hub to receive regular updates, provide feedback and participate in discussions: https://investors.inviongroup.com/ For more information, go to www.inviongroup.com Investor and Media enquiries: Thian Chew (Chairman & CEO) Brendon Lau (Investor & Med